BACKGROUND: CT-2103 (Cell Therapeutics, Seattle, Wash.) is a water-soluble macromolecular conjugate of paclitaxel to a polyglutamate backbone, designed to enhance tumor permeability and to improve intratumoral delivery of paclitaxel. Preclinical studies indicate that CT-2103 has substantial antitumor efficacy in xenograft tumor models. METHODS: We performed a phase I trial in patients with advanced solid tumors to determine the maximum tolerated doses (MTD) of CT-2103 when administered as short intravenous infusion every 3 weeks. RESULTS: Seven patients received a total of 16 cycles (range 1-3) of CT-2103 at doses of 235 and 270 mg/m(2). Two of five patients treated at 235 mg/m(2) and one of two patients treated at 270 mg/m(2) experienced grade 3/4 neutropenia. Four patients experienced a marked increase in PTT within 30 min of the start of infusion. Neuropathy was more severe than expected. Two patients developed grade 3 neuropathy that prompted a 50% dose reduction of CT-2103 and persisted for 8 months in one, and over a year in the other. Three patients experienced grade 1 or 2 neuropathy. Neurotoxicity was cumulative and prevented patients from receiving prolonged administration of CT-2103. CONCLUSIONS: The unexpectedly high rate of cumulative toxicity observed in our study needs to be taken into consideration in future trials of CT-2103. Prior taxane use may not be a predictor of severe neurotoxicity.
BACKGROUND:CT-2103 (Cell Therapeutics, Seattle, Wash.) is a water-soluble macromolecular conjugate of paclitaxel to a polyglutamate backbone, designed to enhance tumor permeability and to improve intratumoral delivery of paclitaxel. Preclinical studies indicate that CT-2103 has substantial antitumor efficacy in xenograft tumor models. METHODS: We performed a phase I trial in patients with advanced solid tumors to determine the maximum tolerated doses (MTD) of CT-2103 when administered as short intravenous infusion every 3 weeks. RESULTS: Seven patients received a total of 16 cycles (range 1-3) of CT-2103 at doses of 235 and 270 mg/m(2). Two of five patients treated at 235 mg/m(2) and one of two patients treated at 270 mg/m(2) experienced grade 3/4 neutropenia. Four patients experienced a marked increase in PTT within 30 min of the start of infusion. Neuropathy was more severe than expected. Two patients developed grade 3 neuropathy that prompted a 50% dose reduction of CT-2103 and persisted for 8 months in one, and over a year in the other. Three patients experienced grade 1 or 2 neuropathy. Neurotoxicity was cumulative and prevented patients from receiving prolonged administration of CT-2103. CONCLUSIONS: The unexpectedly high rate of cumulative toxicity observed in our study needs to be taken into consideration in future trials of CT-2103. Prior taxane use may not be a predictor of severe neurotoxicity.
Authors: Sang Van; Sanjib K Das; Xinghe Wang; Zhongling Feng; Yi Jin; Zheng Hou; Fu Chen; Annie Pham; Nan Jiang; Stephen B Howell; Lei Yu Journal: Int J Nanomedicine Date: 2010-10-21
Authors: Mark A Morgan; Kathleen M Darcy; Peter G Rose; Koen DeGeest; Michael A Bookman; James K Aikins; Michael W Sill; Robert S Mannel; Cecilia Allievi; Merrill J Egorin Journal: Gynecol Oncol Date: 2008-07-01 Impact factor: 5.482
Authors: Stephan T Stern; Peng Zou; Sarah Skoczen; Sherwin Xie; Barry Liboiron; Troy Harasym; Paul Tardi; Lawrence D Mayer; Scott E McNeil Journal: J Control Release Date: 2013-05-09 Impact factor: 9.776
Authors: Yuwei Wang; Jihua Liu; Jun Zhang; Liping Wang; Jonathon Chan; Hai Wang; Yi Jin; Lei Yu; David W Grainger; Wenbin Ying Journal: Int J Med Sci Date: 2014-03-18 Impact factor: 3.738